Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL.

What was studied

This is a 3-year update of the TRANSCEND FL trial. It tested lisocabtagene maraleucel (liso-cel) in relapsed or refractory follicular lymphoma (FL). The main analysis showed high response rates and favourable safety. Longer follow-up was needed to judge remission durability and late toxicities. The update covers patients with later-line (3L+) FL. Patients had relapsed or refractory FL after at least 2 earlier lines of systemic therapy. These included an anti-CD20 antibody and an alkylator. Median follow-up was 41.5 months, with a range of 0.3 to 54.0. 107 patients got liso-cel. 103 could be assessed for efficacy.

What they found

The overall response rate was 97, with a range of 92 to 99. The complete response rate was 94, with a range of 88 to 98. Medians were not reached for time-to-event outcomes. The estimated 36-month rates were 70 for duration of response and 68 for progression-free survival. They were 75 for time free from next treatment and 86 for overall survival. Response and 36-month rates were consistent in high-risk subgroups. Grade 3 or higher cytopenias and low immunoglobulin G fell over time. Most supportive care was needed within 3 months after infusion. Grade 3 or higher infections stayed low in short and long periods.

What it means for patients

The authors say a single liso-cel infusion gave durable efficacy. They say survival was high at 3 years. This included high-risk subgroups. They say the long-term safety profile was favourable.

Why it is not certain yet

Medians were not reached for time-to-event outcomes. Follow-up ranged from 0.3 to 54.0 months. The abstract gives no comparison group. A single trial can only show so much.

Source

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL.

We restate facts from the source record in our own words. The original wording belongs to its publisher.